STAT January 12, 2025
Adam Feuerstein

In pre-JPM interview, Viehbacher says rare disease, immunology, and neurology are of interest

SAN FRANCISCO — Biogen would like to make additional biotech acquisitions in 2025 beyond Friday’s offer to buy its financially troubled partner...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Interview / Q&A, Pharma / Biotech, Trends
Our Sleep, Brain Aging, and Waste Clearance
Tune raises $175M for hepatitis B medicine, epigenetic research
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Open Source in Life Sciences: Balancing Innovation and Compliance
The hidden traps of business building: A guide for life science CEOs

Share This Article